Revolutionary Immunotherapy for Cancer Treatment

Cancer immunotherapy has reshaped modern medicine, offering hope by training the body’s own immune system to recognize and destroy cancer cells. However, while existing immunotherapies have delivered remarkable results for some patients, many others see little to no benefit. Now, researchers from the Massachusetts Institute of Technology (MIT) and Stanford University have unveiled a promising new approach that could significantly expand the reach of immunotherapy to more cancer patients worldwide .

The new strategy focuses on disabling a lesser-known immune “brake” used by tumors to evade immune attack. By targeting sugar molecules—called glycans—on the surface of cancer cells, scientists have created a novel therapeutic design that enhances immune activation and suppresses tumor growth more effectively than current methods alone.

Understanding Immune Checkpoints in Cancer

The immune system is designed to identify and eliminate harmful cells, including cancerous ones. However, tumors often exploit natural immune-regulating mechanisms—known as immune checkpoints—to escape destruction. The most well-known checkpoint involves the interaction between PD-1, a receptor on immune cells, and PD-L1, a protein expressed on cancer cells. Blocking this interaction has led to widely used checkpoint inhibitor drugs that have revolutionized treatment for cancers such as melanoma, lung cancer, and kidney cancer .

Despite these successes, PD-1–based therapies fail to help a large percentage of patients. This limitation has pushed scientists to search for additional immune checkpoints that could be targeted to improve outcomes.

Glycans: A Hidden Immune Suppression Pathway

The MIT–Stanford team turned their attention to glycans—complex sugar molecules found on the surface of all cells. Cancer cells often display abnormal glycan patterns, including high levels of sialic acid–containing glycans. These molecules bind to receptors called Siglecs (sialic acid–binding immunoglobulin-type lectins) on immune cells, triggering a suppressive signal that prevents immune activation .

“When Siglec receptors on immune cells interact with sialic acids on tumor cells, the immune response is effectively shut down,” explained lead researcher Dr. Jessica Stark of MIT. “This mechanism works very much like the PD-1 checkpoint, but it has remained largely untapped in cancer therapy.”

Introducing AbLecs: A New Class of Cancer Therapeutics

To block this glycan-based immune checkpoint, the researchers engineered hybrid protein molecules called AbLecs—short for antibody-lectin chimeras. These innovative molecules combine two powerful components:

• An antibody that precisely targets cancer cells

• A lectin that binds to sialic acid glycans and prevents immune suppression

By linking these two elements, AbLecs deliver lectins directly to the tumor surface, overcoming previous limitations where lectins alone failed to bind strongly enough to be therapeutically effective.

“Once the AbLec reaches the cancer cell, it blocks sialic acids from engaging Siglec receptors,” Stark said. “This leads to release of the immune brakes, allowing immune cells to attack the tumor.”

Promising Results in Laboratory and Animal Studies

The researchers tested AbLecs using trastuzumab, a widely used antibody therapy for HER2-positive cancers such as breast and gastric cancer. Laboratory experiments showed that AbLecs dramatically improved immune cell activity, enabling macrophages and natural killer (NK) cells to destroy cancer cells more efficiently than trastuzumab alone .

In mouse models engineered to mimic human immune systems, treatment with AbLecs led to significantly fewer lung metastases compared with standard antibody therapy. These findings suggest that AbLecs may offer a powerful new way to enhance existing cancer treatments rather than replace them.

A Flexible, Plug-and-Play System

One of the most compelling aspects of AbLec technology is its modular design. Scientists can swap different antibodies to target various cancer types, including those expressing HER2, CD20, or EGFR. Similarly, different lectins can be incorporated to block other glycan-based immune suppressive pathways.

“This flexibility means AbLecs could potentially be adapted for many cancers,” said Stark. “This plug-and-play system allows customization of tumor biology treatments.”

Such adaptability is especially important given the diversity of cancer types and patient responses, including those seen across global populations such as the Middle East.

Toward Clinical Trials and Future Therapies

The research team has co-founded Valora Therapeutics, a biotechnology startup focused on advancing AbLec candidates toward human clinical trials. Early-stage trials could begin within the next two to three years, pending regulatory approvals.

If successful, AbLecs could represent a new frontier in cancer immunotherapy—one that works alongside existing checkpoint inhibitors to improve outcomes for patients who currently have limited treatment options.

Why This Matters Globally

Cancer remains a leading cause of death worldwide, including across the Gulf region. Innovative therapies that enhance immune responses without significantly increasing toxicity are critical for improving survival rates and quality of life. By targeting glycan-based immune checkpoints, this research opens the door to more inclusive and effective cancer treatments for diverse populations .

References

1. Stark, Jessica C., et al. “Antibody-Lectin Chimeras for Glyco-Immune Checkpoint Blockade.” Nature Biotechnology, 16 Dec. 2025, doi:10.1038/s41587-025-02884-6.

2. National Cancer Institute. “Cancer Immunotherapy.” NIH, www.cancer.gov/about-cancer/treatment/types/immunotherapy.

3. Varki, Ajit, et al. “Sialic Acids in Human Health and Disease.” Trends in Molecular Medicine, vol. 23, no. 4, 2017, pp. 351–364.

4. World Health Organization. “Cancer Fact Sheet.” WHO, 2024, www.who.int/news-room/fact-sheets/detail/cancer.